PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a randomized, phase III trial led by researchers at MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login